Sudo Biosciences, a Menlo Park, CA-based biopharmaceutical company, raised $37M in Series A funding.
The round was led by Frazier Life Sciences with participation from Velosity Capital.
The company intends to use the funds to advance its lead drug candidates into the clinic.
Led by CEO Scott Byrd, Sudo Biosciences is a biopharmaceutical company focused on designing and developing medicines to improve patients’ lives. The company’s programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
Sudo Biosciences also has operations in Indianapolis, IN and London, UK.
FinSMEs
29/09/2022